- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic heart failure
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 PBAC Meeting - (PDF 370KB)
- Public Summary Document (PSD) November 2024 PBAC Meeting - (Word 78KB)
Sacubitril with valsartan – November 2024
Sacubitril with Valsartan; Tablet containing sacubitril 24.3 mg with valsartan 25.7 mg, Tablet containing sacubitril 48.6 mg with valsartan 51.4 mg, Tablet containing sacubitril 97.2 mg with valsartan 102.8 mg; Entresto®
Last updated
30 May 2025
